格隆汇1月27日丨康众医疗(688607.SH)公布，经财务部门初步测算，公司2025年年度实现归属于母公司 所有者的净利润与上年同期（法定披露数据）相比，将减少2,265.27万元到2,665.27万元，同比减少 128.32%到150.98%。实现归属于母公司所有者的净利润-900万元到-500万元。预计公司2025年年度实现 归属于母公司所有者的扣除非经常性损益的净利润与上年同期（法定披露数据）相比，将减少1,794.42 万元到2,394.42万元，同比减少301.88%到402.82%。归属于母公司所有者扣除非经常性损益后的净利 润-1,800万元到-1,200万元。 2025年度，受宏观经济形势下行、地缘政治冲突影响，关税剧烈波动，使得公司产品毛利下降；同时新 产品及新业务新产品及新业务处于市场导入期，前期必要的研发与市场投入较大，相关费用短期内对利 润形成压力。 ...

Core Viewpoint - Kangzhong Medical (688607.SH) is expected to report a significant decline in net profit for the year 2025, with projections indicating a decrease of 22.65 million to 26.65 million yuan, representing a year-on-year decline of 128.32% to 150.98% [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company ranging from -9 million to -5 million yuan for 2025 [1] - The expected net profit after deducting non-recurring gains and losses is projected to decrease by 17.94 million to 23.94 million yuan, reflecting a year-on-year decline of 301.88% to 402.82% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is forecasted to be between -18 million and -12 million yuan [1] Influencing Factors - The decline in profitability is attributed to the downturn in the macroeconomic environment and geopolitical conflicts, which have led to significant fluctuations in tariffs, adversely affecting product gross margins [1] - The introduction of new products and business lines is still in the market penetration phase, requiring substantial upfront research and market investment, which is exerting short-term pressure on profits [1]